St. Jude Medical
This article was originally published in The Gray Sheet
Medtronic's October Sprint Fidelis ICD lead recall resulted in a "one-time," $20 million bump up for St. Jude in the 2007 fourth quarter, contributing to $637 million in Q4 cardiac rhythm management sales, an increase of 19% from the prior-year period, St. Jude announced Jan. 23. The added revenue came almost entirely from Japan, where Medtronic did not get approval to market a Fidelis alternative until this month (1"The Gray Sheet" Oct. 22, 2007, p. 3). St. Jude exceeded $1 billion in total revenue in a single quarter for the first time in Q4, reporting $1.02 billion, up 18% from 2006. For the full year, the firm reported a 14% up tick to $3.78 billion, including double-digit growth in its CRM, atrial fibrillation and neuromodulation units
You may also be interested in...
Medtronic's sales of implantable cardioverter defibrillators beat analyst expectations in the most recent fiscal quarter despite lingering fall-out from the firm's October Fidelis ICD lead recall
Medtronic's decision to halt worldwide distribution of its Sprint Fidelis defibrillator leads has attracted congressional scrutiny of the company's response to data showing the leads were vulnerable to fracture
AstraZeneca's research head admits that half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.